CreoSG (formerly Qurocom) has initiated a company name change and a restructuring of its business to focus on bio, and has appointed a bio expert as CEO to strengthen research and development and actively promote collaboration with leading bio companies. CreoSG announced on the 1st that it has newly appointed Lee Sang-gyun as CEO.
The newly appointed CEO Lee Sang-gyun is a bio expert who completed his bachelor's and master's degrees at Seoul National University and earned a Ph.D. in Toxicology from Iowa State University in the United States. He has experience in various new drug development projects at LG Life Sciences Technology Research Institute and has been overseeing bio-related work such as new drug development platform development and AIDS vaccine development at Smagen since 2006.
During his tenure, many former LG Life Sciences Technology Research Institute members, with whom he closely collaborated, are now positioned at leading bio companies, providing a solid industry network. He has maintained close relationships with executives of major domestic bio companies such as Alteogen and LegoChem Biosciences. He has been providing business-related advice to Alteogen since its early establishment and has experience in building new drug development processes as a founding member of LegoChem Bio, enabling not only simple personal networks but also practical business development discussions in specialized fields.
With this CEO appointment as a turning point, the commercialization of CreoSG’s new drug pipeline is expected to accelerate. CreoSG recently succeeded in developing a universal vaccine development platform called ‘SUV-MAP.’ SUV-MAP, developed by CEO Lee Sang-gyun, has the major advantage of enabling rapid response within five months in the event of a pandemic by utilizing its own gene synthesis capabilities. It can develop vaccines not only for viruses but also for bacteria, making it applicable to the prevention of various diseases.
A CreoSG official said, “The appointment of CEO Lee Sang-gyun signifies that CreoSG will practically lead the bio business,” adding, “With Lee, who has been responsible for research and development through subsidiaries, stepping to the forefront, we expect to strengthen R&D cooperation by leveraging networks with leading domestic and international bio companies.”
He added, “After the company name change, we plan to concentrate the company-wide capabilities on the bio business, which will help visualize the achievements of CreoSG’s new drug development business.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
